Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | POLB | P06746 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL11669278 | 0.98 | SIGMAR1 (0.47) | SIGMAR1CYP2C9CYP2C19MAPTDDB1 | |
| Hydrochloric Acid SCHEMBL8465643 | 0.88 | L3MBTL1 (0.47) | SIGMAR1CYP2C9CYP2C19MAPTDDB1 | |
| SCHEMBL6663737 | 0.84 | SLC6A3 (0.46) | SIGMAR1ALDH1A1SMN1; SMN2CYP2D6CYP1A2 | |
| SCHEMBL24709610 | 0.83 | ALDH1A1 (0.46) | SIGMAR1CYP2C9CYP2C19MAPTKMT2A | |
| SCHEMBL20569065 | 0.83 | HPGD (0.45) | CYP2C9CYP2C19MAPTALDH1A1POLB | |
| SCHEMBL24709604 | 0.81 | ALDH1A1 (0.45) | CYP2C9CYP2C19MAPTALDH1A1POLB | |
| SCHEMBL24709613 | 0.81 | SMN1; SMN2 (0.57) | KMT2AMEN1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL24709607 | 0.81 | ALDH1A1 (0.67) | CYP2C9CYP2C19MAPTALDH1A1POLB | |
| Bromide SCHEMBL31141392 | 0.81 | ALDH1A1 (0.45) | SIGMAR1CYP2C9CYP2C19MAPTKMT2A | |
| SCHEMBL7999499 | 0.81 | CHRNB2 (0.54) | ALDH1A1TDP1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022257581-A1 | A CLASS OF IMIDAZOLIDINOPYRIMIDONE COMPOUNDS AND USE THEREOF IN TREATMENT OF HSCLPP-MEDIATED DISEASES | 四川大学 | 2022-12-15 | — | — | WO | disclosed |
| US-8293768-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120004164-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-05 | — | — | US | disclosed |
| US-8063084-B2 | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels | NOVARTIS AG (CH) | 2011-11-22 | — | — | US | disclosed |
| US-20100233116-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-16 | — | — | US | disclosed |
| EP-2054408-A2 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL | Novartis Ag (CH) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008127349-A2 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | disclosed |
| EP-1296958-A4 | IMINOPYRIMIDINE NMDA NR2B RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002000629-A9 | IMINOPYRIMIDINE NMDA NR2B RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2003-05-15 | — | — | WO | disclosed |
| EP-1296958-A1 | IMINOPYRIMIDINE NMDA NR2B RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| US-6440976-B2 | FOR THERAPY OF PAIN, MIGRAINE, DEPRESSION, ANXIETY, SCHIZOPHRENIA, PARKINSON'S DISEASE, STROKE, AND IN THERAPY OF NEUROPATHIES INCLUDING POSTHERPETIC NEURALGIA, CENTRAL PAIN FROM SPINAL CORD INJURY, AND PHANTOM LIMB PAIN | MERCK & CO., INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020013329-A1 | Iminopyrimidine NMDA NR2B receptor antagonists | MERCK & CO., INC. | 2002-01-31 | — | — | US | disclosed |
| WO-2002000629-A1 | IMINOPYRIMIDINE NMDA NR2B RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233116-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SIGMAR1 1043/4885CYP2C9 608/4885CYP2C19 1135/4885 |
| US-20120004164-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SIGMAR1 1260/4885CYP2C9 213/4885CYP2C19 436/4885 |
| US-20020013329-A1 | Iminopyrimidine NMDA NR2B receptor antagonists | GRIN1, GRIN2B, GRIN2C | SIGMAR1 338/4885CYP2C9 3179/4885CYP2C19 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.